Recent Transactions

23-Nov-16
$NA
Israel flag
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

14-Nov-16
$748 million
United States flag
Target: 

Peacock Foods

U.K., Ireland flags
Acquiror: 
Greencore Group plc

Advised Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.

14-Nov-16
$NA
Japan, Australia flags
Target: 

Lion’s Australian Premium Wine Business – Fine Wine Partners

Australia flag
Acquiror: 
Accolade Wines

Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity

03-Nov-16
$NA
Switzerland flag
Target: 

Fragrance Resources Group

United States flag
Acquiror: 
International Flavors & Fragrances Inc.

Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland

17-Oct-16
$1.4 billion
United States flag
Target: 

Save-A-Lot

Canada flag
Acquiror: 
Affiliate of Onex Corporation

Advised SUPERVALU, Inc., one of the largest grocery wholesalers and retailers in the US, on the sale of its Save-A-Lot business, a leading hard-discount grocery retailer in the U.S., to an affiliate of Onex Corporation 

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

28-Jul-16
$80 million
United States flag
Target: 

BioD, LLC

United States flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

28-Jun-16
$NA
Israel flag
Target: 

US rights to an authorized generic version of Adderall XR

United States flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

28-Jun-16
$652 million
Israel flag
Target: 

US rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

21-Jun-16
$586 million
Israel flag
Target: 

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

20-Jun-16
$NA
Israel flag
Target: 

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

17-Jun-16
$310 million
United Kingdom flag
Target: 

Dobbies Garden Centres

United Kingdom flag
Acquiror: 
Investor group led by Midlothian Capital Partners and Hattington Capital

Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital

16-Jun-16
$40 million
Israel flag
Target: 

US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

15-Jun-16
$414 million
United States flag
Target: 

Aegerion Pharmaceuticals

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

11-Jun-16
$350 million
Israel flag
Target: 

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

10-Jun-16
$NA
United Kingdom flag
Target: 

Giraffe restaurants

United Kingdom flag
Acquiror: 
Boparan Private Office

Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan

01-Jun-16
$221 million
Australia flag
Target: 

Patties Foods Ltd

Australia flag
Acquiror: 
Pacific Equity Partners

Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement

04-May-16
$NA
United States flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

United States flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

02-May-16
$NA
United States flag
Target: 

Fairway Group Holdings Corp.

flag not available

Advised Fairway Group Holdings Corp., a grocery store chain operating fifteen stores in the New York metropolitan area, in connection with its pre-packaged Chapter 11 bankruptcy plan

19-Apr-16
$NA
United States flag
Target: 

Total Care Medicaid Plan

United States flag
Acquiror: 
Molina Healthcare, Inc.

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

07-Mar-16
$NA
Germany flag
Target: 

Boehringer Ingelheim

United States flag
Acquiror: 
AbbVie

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

19-Jan-16
$NA
Brazil flag
Target: 

Recepta Biopharma

Brazil flag
Acquiror: 
Inova Empresa Fundo de Investimento em Participações

Advised Recepta Biopharma on a capital raise

Pages

show all